Enterprise Value
3.455B
Cash
1.883B
Avg Qtr Burn
-87.93M
Short % of Float
15.96%
Insider Ownership
1.49%
Institutional Own.
67.98%
Qtr Updated
03/31/23
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
BLA Acceptance for review | ||
BLA Acceptance for review | ||
CTX110 (CD19) Details CD19+ malignancies, Blood cancer, Cancer, B-cell malignancies | Phase 2 Data readout | |
Phase 1/2 Update | ||
Phase 1/2 Update | ||
VCTX210 Details Type 1 diabetes | Phase 1 Data readout | |
CTX130 (CD70) Details Solid tumor/s, Blood cancer, Cancer | Phase 1 Update | |
CTX120 (BCMA) Details Multiple myeloma, Blood cancer, Cancer | Failed Discontinued |